| Document |
Document Title |
|
WO/2024/094098A1 |
Provided in the present application are a compound for a delivery system and the use thereof, and an ionizable lipid having a hydrogen bond providing group.
|
|
WO/2024/094637A1 |
The present invention relates to a process for the preparation of cyclobutenone derivatives of formula (1), wherein Y is O or NH, R is -C(O)-R1 or -S(0)2-R1, and R' is selected from optionally substituted linear or branched C1-12 alkyl, ...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/075988A1 |
The present invention relates to a urea solution efflorescence detergent additive and a preparation method therefor. By providing a urea solution efflorescence detergent additive, which is prepared through: a mixture preparation step (S1...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
|
WO/2023/196444A1 |
Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component o...
|
|
WO/2023/176921A1 |
Disclosed is a urea production method and a urea production apparatus with which hydrogen and oxygen are generated by electrolysis of water in an electrolysis unit (E), nitrogen is separated from air and recovered in an air separation un...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/158584A1 |
The invention provides new bicyclopentanyl compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, and R5 are as defined herein, compositions including the compounds, ...
|
|
WO/2023/145821A1 |
Disclosed is a urea synthesis method in which a urea synthetic liquid produced in a urea synthesis tower A is brought into contact, under heat, with at least a part of raw material carbon dioxide in a stripper C, separated mixed gas is i...
|
|
WO/2023/131677A1 |
The inventors have succeeded in developing urea, oxalamide, amide, thiourea, carbamate or ester compounds, in particular urea compounds, bearing two side groups, one of which carries a hydroxyphenyl or phenyl moiety, in particular a hydr...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/108277A1 |
The present invention relates to application of hydrotropic agents in making water-soluble and super-fast disintegrating tablets, buccal tablets, or sublingual tablets containing either cannabinoid molecules or psychedelics molecules. Th...
|
|
WO/2023/106377A1 |
Provided is a method for producing a blocked isocyanate compound, the method comprising a reaction step of reacting a primary amine compound, a carbonic acid derivative, and a blocking agent by means of heat treatment in the presence of ...
|
|
WO/2023/098072A1 |
Provided are a Nectin-4-targeted bicyclic peptide nuclide ligand and probe. The ligand has a structure represented by formula I, where X is Lys or Arg; and R is a group represented by formula II, formula III, formula IV or formula V. The...
|
|
WO/2023/092242A1 |
The present application includes dendrons of Formula I, compositions comprising these dendrons and uses thereof, in particular for the delivery of agents such as nucleic acids and drugs to cells and subjects. (I) wherein each Repeating G...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/091490A1 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2023/091679A1 |
Provided herein are compounds and methods for modulating claudin-1 (CLDN1). More particularly, provided are inhibitors claudin-1 and the uses of such inhibitors in regulating diseases and disorders, e.g., to treat cancer.
|
|
WO/2023/077041A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/074937A1 |
The present description pertains to a novel compound as a ligand binding to a UBR box domain that is involved in an intracellular protein degradation pathway, and a use thereof.
|
|
WO/2023/064519A1 |
The present invention concerns a co-crystal of Elacestrant dihydrochloride and urea, its use in the preparation of another solid state form of Elecestrant or a salt thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/058022A1 |
This invention, in some embodiments thereof, provides a core- shell nanoparticle including a lipid-PSMA conjugate, encapsulating a liquid oil-based core. The invention further provides aqueous compositions including the core-shell nanopa...
|
|
WO/2023/054417A1 |
Provided as an extraction agent capable of selectively extracting lithium salt is a lithium salt extraction agent which is at least one compound selected from the group consisting of compounds represented by general formula (1) and compo...
|
|
WO/2023/046882A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of ...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/039408A1 |
The present invention relates to the treatment of chronic obstructive pulmonary disease (COPD). More specifically, embodiments of the invention provide a pharmaceutical carrier and a compound that inhibit the induction of MMP-1 expressio...
|
|
WO/2023/008579A1 |
The present invention provides a blocking agent dissociation catalyst for a blocked isocyanate, the blocking agent dissociation catalyst containing a zwitterionic compound represented by formula (1). Formula (1): (In the formula, A, R1, ...
|
|
WO/2023/007147A1 |
This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nic...
|
|
WO/2023/008556A1 |
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especia...
|
|
WO/2023/286719A1 |
The present invention addresses the problem of providing: an industrially advantageous method for producing a uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound; and a ureidomethylene compou...
|
|
WO/2022/266753A1 |
There are provided conjugates of Formula (V) wherein R1 is a triantennary targeting moiety comprising N-acetyl galactosamine and R2 is a bioactive agent which is preferably an oligonucleotide, as well as pharmaceutical compositions and m...
|
|
WO/2022/263944A1 |
An azido-containing monomer, a polymer containing monomeric units derived from the azido-containing monomer, and various articles containing a substrate and a coating layer of the polymer positioned on the substrate are provided. The azi...
|
|
WO/2022/259219A1 |
The present invention relates to novel melatonin ligands capable of modulating the melatonin receptors, particularly the melatonin receptor subtype MT2. Moreover, these compounds have been shown to be effective in the treatment of diseas...
|
|
WO/2022/253785A2 |
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to...
|
|
WO/2022/236270A1 |
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
|
|
WO/2022/232142A1 |
Disclosed herein, inter alia, are G-alpha-s Inhibitors and uses thereof.
|
|
WO/2022/200105A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2022/181695A1 |
The purpose of the present disclosure is to provide: a complex of a cell and a material; a method for producing a complex of a cell and a material; and a novel compound that can be used to obtain said complex. In a complex according to...
|
|
WO/2022/163335A1 |
The purpose of the present invention is to provide a photosensitive resin composition and compound having a low dielectric loss tangent when made into a cured film. The present invention is a photosensitive resin composition containing (...
|
|
WO/2022/155273A1 |
Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/106636A1 |
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...
|
|
WO/2022/106083A1 |
A process for the production of biuret from urea wherein: a urea aqueous solution (24) withdrawn from the recovery section of a urea plant is processed to remove water and obtain a concentrated urea melt (25); said urea melt is processed...
|
|
WO/2022/102557A1 |
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...
|
|
WO/2022/104148A1 |
Disclosed herein, inter alia, are compounds for inhibiting IREl α and uses thereof.
|
|
WO/2022/089774A1 |
The invention relates to a process for preparing 1,2'-benzisothiazoline-3-one according to formula (I), comprising the following steps: (a) reacting a 2-halogenbenzonitrile compound of general formula (II) with a reaction mixture, contai...
|
|
WO/2022/078533A1 |
The present invention relates to substituted 1-phenyl-3-yl-urea derivatives of the general formula (I), and preparations containing these derivatives, (I) wherein Y is nitrogen or carbon; R1 is halogen, methoxy group, methylsulfanyl grou...
|
